WntResearch AB announced that the Patient recruitment for the ongoing Phase IIa clinical study NeoFox with WntResearch's drug candidate Foxy-5 continues. Despite a significant negative impact of covid-19, an aditional 12 patients were randomized during the first quarter of 2021 totaling the number of randomisez patients to 70. The recruitmentrate of new patients in the study is currently reduced since only half of the participating clinics in the study are actively recruiting. WntResearch aims to increase the recruitmenrate during the summer by restoring full activity at all 28 participating clinics in Hungary and Spain, provided that the negative effects of covid-19 have diminished.